NASDAQ:KDNY - Nasdaq - US16961L1061 - Common Stock - Currency: USD
These stocks climbed 74% and 78% over the past month and there could be more gains ahead.
Mentions: VERA
SEATTLE, July 28, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development...
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Chinook Therapeutics, Inc. ("Chinook" or the "Company") (NASDAQ: KDNY). Such...
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Chinook Therapeutics, Inc. ("Chinook" or the "Company") (NASDAQ: KDNY). Such...
Chinook Therapeutics has a history of being opportunistic. Now, it's joining forces with Novartis.
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Chinook Therapeutics, Inc. ("Chinook" or the "Company") (NASDAQ: KDNY). Such...
The company announced early phase 2 trials information regarding its lead therapy.
CHK-336 was generally well tolerated in healthy volunteers (HV) who received single doses up to 500 mg and multiple doses up to 60 mg for 14...
Stocks kept powering higher despite, but the Nasdaq is looking extended.
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Chinook Therapeutics, Inc. ("Chinook" or the "Company") (NASDAQ: KDNY). Such...